Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

India authorizes 2 COVID-19 vaccines

By Brian Buntz | January 4, 2021

India map

Image courtesy of Wikipedia

India is allowing reserved emergency use of the AstraZeneca (LON:AZN) COVID-19 vaccine and another from the domestic firm Bharat Biotech. 

The country is producing both vaccines internally. Serum Institute of India has a contract to manufacture the AstraZeneca vaccine and has stockpiled between 40 and 50 million doses. 

Covaxin, the vaccine from Bharat Biotech, was the result of a collaboration with India’s National Institute of Virology. 

The Bharat Biotech vaccine’s approval has prompted criticism from the All India Drug Action Network, which stated it was “shocked” at the news. “Disturbingly, it appears that no efficacy data for the vaccine candidate were submitted from the Phase 3 trials that are ongoing and being conducted by Bharat Biotech and ICMR,” the organization said in a statement. 

Dr. V.G. Somani, the country’s drug controller, announced the approvals at a news conference yesterday, stating that the country’s regulator, the Central Drugs Standard Control Organization, had a “careful examination” of both vaccines. 

Somani also stressed that Covaxin was “safe and provides a robust immune response.” 

Dr. Krishna Ella, the founder and chairman of Bharat Biotech, echoed that sentiment, explaining at a press conference that the company had performed clinical trials in more than 12 countries for the vaccine. “We are not just an Indian company — we are truly a global company,” he said.

The company has included approximately 26,000 participants in its Phase 3 clinical trials. 

The Bharat Biotech vaccine, like most others, requires two doses. 

The Serum Institute has also encountered delays when producing the AstraZeneca vaccine. It had committed to making 400 million doses by the end of 2020, but to date has produced 350 million less than that. 

In addition to supplying India, the organization also plans on manufacturing vaccines for developing nations.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Moderna and NIH assessing whether COVID-19 vaccine doses can be halved
Timing of COVID-19 vaccine doses sparks debate  
FDA logo
FDA OKs first generic drug to treat severe hypoglycemia
AstraZeneca
AstraZeneca vaccine recipients in U.K. will wait up to 12 weeks for second dose

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards